Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

owth and future development of the company, future acquisitions or dispositions of assets and guidance with respect to expected results of operation. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the company's ability to realize the benefits of its strategic restructuring plan, market conditions and other factors that may influence the company's determination as to whether and when to repurchase its securities, the ability of the company to complete the programs in compliance with applicable requirements, and other risks and uncertainties discussed in the company's annual report on Form 10-K for the year ended December 31, 2007 and other filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

Non-GAAP Information:

To supplement the consolidated financial results prepared in accordance with generally accepted accounting principles (GAAP), the company uses non- GAAP financial measures that exclude certain items, such as in-process research and development, restructuring, amortization, gain on early extinguishment of debt, and certain taxes. Management does not consider the excluded items part of day-to-day business or r
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... and LONDON, UK (PRWEB) March 27, 2015 ... DrugDev SiteStart Melissa (Liss) Easy was named to the ... The 40 Under 40 list spotlights 40 dynamic, up-and-coming ... professional accomplishments and community involvement. Winners are honored at ... special supplement of the Philadelphia Business Journal. , Lyn ...
(Date:3/27/2015)... USA (PRWEB) March 27, 2015 According ... rates of newborns born with Neonatal Abstinence Syndrome (NAS) ... NAS will undergo the painful withdrawal process for a ... body tremors, excessive crying, diarrhea, and vomiting. The condition ... undergoing drug and alcohol addiction treatment (and employing medically ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... To address their number one lawn care ... year filming this video to explain the complicated dynamics between ... it's often expected to thrive in, be it in dense ... to survive. Anytime a sun-loving plant is put in the ... Many homeowners try to amend this issue by applying large ...
Breaking Medicine News(10 mins):Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:For Spring Turf Planting Season, Super-Sod Created a New How-To Video Entitled "Two Views on Shade and Turf" 2
... campaign had failed to hand out morning-after pills to ... pregnancies.// The campaign has neither reduced conception nor abortion ... accused of fuelling record levels of sexually transmitted diseases. ... the Government has spent ? 138million on its Teenage ...
... a public awareness campaign warning people against undertaking ... ,The surgeons have cautioned that undergoing ... and chemical peels, which if performed by improperly ... even death in some cases. ...
... marks the rapid increase in esophageal cancer cases in the US. ... Only 16 % or around 2,200, of the 14,000-esophageal cancer cases ... ,There has been a 6-fold annual rise in the number ... experts. Rise in obesity cases has been the major cause. ...
... FDA, an epidemic of E. coli that has left one ... be associated with bagged fresh spinach.// ,"The FDA ... time and that any individuals who believe they may have ... their health care provider," Dr. David Acheson, head of the ...
... out if metastasis from the eye cancer will make its ... University School of Medicine in St. Louis have developed a ... might spread to the liver, where it could quickly transform ... opinion that the molecular screening test might one day help ...
... given ?5,000 to retrain themselves to work ... Andy Kerr said that the Scottish Executive ... years on this plan.// ,This plan ... trained outside Europe and are not licensed ...
Cached Medicine News:Health News:Government Failed to Prevent Rising Teen Pregnancies 2Health News:Government Failed to Prevent Rising Teen Pregnancies 3Health News:Campaign Against Cosmetic Surgeries Performed By Less-Skilled Non-physicians Launched 2Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... MEETING, Pa., Feb. 10 Genaera Corporation (Nasdaq: ... clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective ... the treatment of type 2 diabetes and obesity. ... data from the first of three cohorts in an ...
... A new study published today claiming that multivitamin ... risk of mortality fails to take into account important ... health claims are regulated by the U.S. Food and ... published in the February 9 issue of Archives ...
Cached Medicine Technology:Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association 2
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
Inquire...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Medicine Products: